Gene
CDKN2C
CDKN2C is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (3), Actionable biomarkers (4), Trial mentions (1), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CDKN2C. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
CDKN2C has 1 trial mention across 1 year. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 3 of 11,460 | 0.03% |
| 2022 | 0 of 8,285 | 0.00% | 4 of 13,598 | 0.03% |
| 2021 | 0 of 8,692 | 0.00% | 7 of 15,045 | 0.05% |
| 2020 | 0 of 7,640 | 0.00% | 3 of 14,459 | 0.02% |
| 2019 | 0 of 7,300 | 0.00% | 3 of 12,159 | 0.02% |
| 2018 | 0 of 6,927 | 0.00% | 3 of 11,854 | 0.03% |
| 2017 | 0 of 6,558 | 0.00% | 9 of 11,595 | 0.08% |
Showing 10 of 37 years.
Assay-provider ledger (3)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Kumei Biotechnology Co. | Reagent supplier | Clinical validationAnalytical validation | 1 | October 01, 2024 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 1 | October 01, 2024 |
| TransGen Biotech | Reagent supplier | Clinical validationAnalytical validation | 1 | October 01, 2024 |
Actionable biomarkers (4)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CDKN2C deletion | Cdk2 Inhibitors | response-associated | glioma | Cancer Genome Interpreter |
| CDKN2C oncogenic mutation | Cdk2 Inhibitors | response-associated | glioma | Cancer Genome Interpreter |
| CDKN2C deletion | Cdk2 Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
| CDKN2C oncogenic mutation | Cdk2 Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (1)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05843253 | Trial eligibility (AACT) |
Target-disease associations (442)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 46,XY partial gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| ATP measurement | measurement | GWAS credible sets |
| Ataxia-telangiectasia | disorder of visual system | Mouse knockout (IMPC) |
| Atypical Meningioma | cancer or benign tumor | Cancer Gene Census |
| Autoimmune lymphoproliferative syndrome with recurrent viral infections | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 442 associations.
Vendor sourcing (6)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.408G>C (p.K136N) alteration is located in exon 3 (coding exon 2) of the CDKN2C gene. This alteration results from a G to C substitution at nucleotide p... | View ClinVar record SCV003592829.2 |
| Memorial Sloan Kettering Cancer Center | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted without stated criteria (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV001132092.1 |
| Nationwide Children's Hospital | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | for assignment to TarGeT-A, for all strata: 2.1) Presence of at least one relevant actionable somatic alteration, detailed here: * Pathogenic alterations p... | View trial NCT05843253 |
| Nationwide Children's Hospital | Trial sponsor | Mentioned in trial textTrial free-text mention | CDKN2C | View trial NCT05843253 |
| Novartis Ag | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | for assignment to TarGeT-A, for all strata: 2.1) Presence of at least one relevant actionable somatic alteration, detailed here: * Pathogenic alterations p... | View trial NCT05843253 |
Showing 5 of 6 sourcing records.
Trial-cited literature (61)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors. | Communications biology | 2023 | 24 |
| Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression. | Cold Spring Harbor molecular case studies | 2023 | 6 |
| Activity of pemetrexed in pre-clinical chordoma models and humans. | Scientific reports | 2023 | 4 |
| Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. | Blood cancer discovery | 2022 | 38 |
| MEN4, the MEN1 Mimicker: A Case Series of three Phenotypically Heterogenous Patients With Unique CDKN1B Mutations. | The Journal of clinical endocrinology and metabolism | 2022 | 27 |
Showing 5 of 61 papers.
Literature-extracted relations (1)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Neoplasms | Disease | associate |
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. | 2023 |
Organizations publishing (97)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Dana-Farber Cancer Institute | Other | 4 | 2014 to 2022 |
| Government of the United States of America | Government | 4 | 2003 to 2022 |
| Memorial Sloan Kettering Cancer Center | Hospital | 4 | 2012 to 2022 |
| Harvard Medical School | Academic | 3 | 2014 to 2022 |
| Mayo Clinic | Hospital | 3 | 2017 to 2022 |
Showing 5 of 97 organizations.
Where CDKN2C appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
409 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, protein variant mentions, and human sample screening reference.